Defendant
5 cases as defendant.
Aerin Medical Inc. is a privately held, venture-backed medical device company founded in 2011 and headquartered in Mountain View, California, with additional offices in Austin, Texas. The company has approximately 101-200 employees. As of December 2024, Aerin Medical raised $32.48 million in Series G funding, co-led by KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation from Ares Capital.
Aerin Medical specializes in innovative, non-invasive treatment solutions for chronic nasal conditions, focusing on nasal airway obstruction (NAO) and chronic rhinitis. Their core products are the VivAer® Stylus for nasal airway obstruction and the RhinAer® Stylus (including the next-generation RhinAer+™ Stylus) for chronic rhinitis. These FDA-cleared devices utilize proprietary temperature-controlled or temperature- and impedance-controlled radiofrequency technology to deliver precise, tissue-sparing treatments that can be performed in a physician's office under local anesthetic.
Aerin Medical Inc. has a patent-litigation posture as a plaintiff, with one tracked case. The company is involved in "Aerin Medical Inc. v. Neurent Medical Ltd. et al.," filed in 2025-06-18 at the Patent Trial and Appeal Board (PTAB) of the USPTO. This indicates that Aerin Medical is asserting its intellectual property, likely challenging the validity of a competitor's patent or defending its own patents against a challenge. Neurent Medical is identified as a competitor by Owler.
This district court case involves Neurent Medical Ltd. suing Aerin Medical Inc. An oral argument on a motion to consolidate cases and stay was held, and the motion was granted-in-part, with parties ordered to prepare consolidation documents and a proposed interim schedule.
Neurent petitioned for inter partes review of all asserted claims of the '286 patent. The Board instituted review and issued a Final Written Decision on July 11, 2025, finding all challenged claims unpatentable as obvious; Aerin appealed.
Neurent Medical Inc. and Neurent Medical Ltd. filed an inter partes review challenging U.S. Patent No. 9,072,597. The Board instituted review on 2024-07-22; the proceeding terminated on 2025-01-24 by adverse judgment after Aerin statutorily disclaimed the '597 claims.
Neurent Medical Inc. and Neurent Medical Ltd. petitioned for inter partes review of US 9,415,194, challenging claims 1–3, 6, 12, 14, 16, 18, and 19. The PTAB instituted on July 22, 2024, and terminated by adverse judgment on January 24, 2025, after Aerin statutorily disclaimed the challenged claims.
Inter partes review petition by Neurent Medical Inc. and Neurent Medical Ltd. challenging claims 1–4, 6–12, and 16 of U.S. Patent 11,241,271. Institution was granted July 22, 2024, and the Final Written Decision of July 11, 2025 held the challenged claims unpatentable as obvious; the patent owner appealed.